Osteoarthritis — an untreatable disease?
The DOI matches its Crossref record; 123 of the 124 references it cites were found in a registry or an index.
Abstract
Osteoarthritis is a painful and disabling disease that affects millions of patients. Its aetiology is largely unknown, but is most likely multi-factorial. Osteoarthritis poses a dilemma: it often begins attacking different joint tissues long before middle age, but cannot be diagnosed until it becomes symptomatic decades later, at which point structural alterations are already quite advanced. In this review, osteoarthritis is considered as a disease of the whole joint that may result from multiple pathophysiological mechanisms, one of which is the dysregulation of lipid homeostasis. No proven disease-modifying therapy exists for osteoarthritis and current treatment options for chronic osteoarthritic pain are insufficient, but new pharmacotherapeutic options are emerging.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a chronic disease characterized by degeneration of articular cartilage leading to pain and physical disability.”
From Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017) · cites this paper as [10]
In the citing paper
“Aging and trauma are risk factors for the development of osteoarthritis (OA)10”
From Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017) · cites this paper as [10]
Citations
Cites
1 retracted
Yagami, K., Uyama, Y., Yoshizawa, Y., Kakuta, S., Yamaguchi, A., & NAGUMO, M. (2004) · Bone · doi:10.1016/j.bone.2003.12.016 · Cited by 17 · cited 1×
“Interestingly, adipocytes share a common mesenchymal stem-cell precursor with osteoblasts and chondrocyte”
BackgroundRetractedCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734 · cited 1×
“COX1 is constitutively expressed in many cell types, whereas COX2 is induced at the site of inflammation, although it is also constitutively expressed in the kidney, for exampl”
BackgroundLeptin Inhibits Bone Formation through a Hypothalamic Relay
Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., & Karsenty, G. (2000) · Cell · doi:10.1016/s0092-8674(00)81558-5 · Cited by 2,077
Jordan, K. M., Arden, N. K., Doherty, M., Bannwarth, B., Bijlsma, J. W. J., Dieppe, P., Gunther, K., Hauselmann, H., Herrero-Beaumont, G., Kaklamanis, P., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011742 · Cited by 2,048 · cited 1×
“It is recommended as a first-line oral analgesic for knee O”
BackgroundCharbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Leptin Regulates Bone Formation via the Sympathetic Nervous System
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., Armstrong, D., Ducy, P., & Karsenty, G. (2002) · Cell · doi:10.1016/s0092-8674(02)01049-8 · Cited by 1,735 · cited 1×
“Besides its role in regulating caloric intake, leptin regulates bone mass and mineralization through a neuroendocrine pathway involving the sympathetic nervous syste”
BackgroundWarner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Ahima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S., Allchorne, A., Poole, S., Bonventre, J. V., & Woolf, C. J. (2001) · Nature · doi:10.1038/35068566 · Cited by 1,281
Research works printed but not linked: 6
- Harris, E. D. Jr. The Bone and Joint decade: a catalyst for progress. Arthritis Rheum 44, 1969–1970 (2004). · doi:10.1002/1529-0131(200109)44:9<1969::aid-art342>3.0.co;2-a
- Brandt, K. D., Smith, G. N. Jr & Simon, L. S. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum. 43, 1192–1203 (2000). · doi:10.1002/1529-0131(200006)43:6<1192::aid-anr2>3.0.co;2-l
- Bingham, C. et al. Clinically significant placebo improvement occurs by 6 months and is maintained through 24 months in a study of knee OA pain and function. Osteoarthr. Cartil. 12, S132 Abs. P323 (2004).
- Flechtenmacher, J. et al. Bradykinin-receptor-inhibition — a therapeutic option in osteoarthritis? Osteoarthr. Cartil. 12, S137 Abs. P332 (2004).
- Ding, C & Cicuttini, F. Licofelone (Merckle). IDrugs 6, 802–808 (2003).
- Schnitzer, T. J., Kivitz, A. J., Lipetz, S., Sanders, N. & Hee, A. A Phase II study of the efficacy and safety of AZD3582, a CINOD, in subjects with osteoarthritis of the knee. Eur. League Against Rheumatism 2004 Conference Abs OP0016 [online], < http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2004SCIE-abstract&TEMPLATE=&keyf=0094&showHide=show&client= > (2004)
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
“In one mouse model, injection of UBX0101 selectively eliminated senescent cells and reduced proteoglycan loss, which alleviated the cartilage degradation and pain caused by OA.339 Fenofibrate, a PPARα agonist, clears SAβ-gal-positive chondrocytes by promoting apoptosis.595 Fisetin, a flavonoid drug, alleviates inflamm…”
BackgroundInfluentialJeon, O. H., Kim, C., Laberge, R.-M., Demaria, M., Rathod, S., Vasserot, A. P., Chung, J. W., Kim, D. H., Poon, Y., David, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4324 · Cited by 1,515
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Proteases involved in cartilage matrix degradation in osteoarthritis
Troeberg, L., & Nagase, H. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.06.020 · Cited by 579
Tang, S., Zhang, C., Oo, W. M., Fu, K., Risberg, M. A., Bierma-Zeinstra, S. M., Neogi, T., Atukorala, I., Malfait, A.-M., Ding, C., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00594-6 · Cited by 476
“Once regarded as a simple ‘wear and tear’ or ‘degenerative’ joint disease, OA is now understood as a complex, multifactorial disorder affecting the entire joint, including the bone, cartilage, ligaments and muscles 2,3 (Fig.”
Metadata
- Authors
- Wieland, H. A., Michaelis, M., Kirschbaum, B. J., & Rudolphi, K. A.
- Affiliations
- Sanofi (Germany) (DE)
- Corresponding author
- Wieland, Heike A.
- ORCID
- Michaelis, Martin
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-04
- Volume
- 4
- Issue
- 4
- Pages
- 331-344
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1487036716
- Cited by
- 585
- References
- 124
- Citations by year
- 2026: 34 · 2025: 32 · 2024: 44 · 2023: 31 · 2022: 36 · 2021: 34 · 2020: 25 · 2019: 36 · 2018: 24 · 2017: 31 · 2016: 26 · 2015: 29 · 2014: 29 · 2013: 32 · 2012: 29
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacological Effects of Medicinal Plants
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- osteoarthritis, disease-modifying therapy, early-onset osteoarthritis, pharmacotherapy, treatment options
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Humans, Osteoarthritis, Pain, Drug Design, Molecular Structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoarthritis — an untreatable disease? https://app.cochat.ai/papers/10.1038/nrd1693
- The paper
- Wieland, H. A., Michaelis, M., Kirschbaum, B. J., & Rudolphi, K. A. (2005). Osteoarthritis — an untreatable disease? Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1693
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.